[{"data":1,"prerenderedAt":142},["ShallowReactive",2],{"drug-desflurane":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":33,"contraindications":56,"warnings":65,"renal":73,"monitoring":74,"interactions":75,"review":76,"examples":79,"atc":80,"iran":82,"links":89,"populations":103,"usApproval":137},"desflurane",1,{"fa":7,"en":8},"دسفلوران","Desflurane","nervous-system",{"fa":11,"en":12},"هوشبر استنشاقی هالوژنه","Halogenated inhalational anaesthetic",[14],{"name":15,"market":16},"Suprane","US",[18,19,7],"suprane","سوپران",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":28,"refs":29},"liq","solution","inhaled","Volatile liquid for dedicated vaporizer (100%)",{"amount":5,"unit":27,"perUnit":27},"application",[16],[30],{"source":31,"section":32},"fda-suprane","3",[34],{"id":35,"disease":36,"label":37,"population":40,"type":41,"unit":42,"dose":43,"refs":47},"ga","general-anesthesia",{"fa":38,"en":39},"نگهداری بیهوشی — بزرگسال ۲٫۵ تا ۸٫۵٪، کودک اینتوبه ۵٫۲ تا ۱۰٪","Maintenance of anaesthesia — adults 2.5–8.5%, intubated children 5.2–10%",{},"notCalculated","mg",{"reason":44},{"fa":45,"en":46},"دوز درصد غلظت است. القا در بزرگسال (شروع ۳٪ با افزایش ۰٫۵ تا ۱٪)؛ برای القای کودکان ممنوع (تحریک راه هوایی). در بیماری کرونر به‌تنهایی برای القا نه.","Dosed as concentration %. Adult induction start 3% in 0.5–1% steps; contraindicated for induction in children (airway irritation). Not as sole induction agent in coronary disease.",[48,50,52,54],{"source":31,"section":49},"2.3",{"source":31,"section":51},"2.2",{"source":31,"section":53},"2.6",{"source":31,"section":55},"4",[57],{"id":58,"severity":59,"text":60,"refs":63},"ci","block",{"fa":61,"en":62},"استعداد ژنتیکی (شناخته یا مشکوک) هیپرترمی بدخیم؛ حساسیت به این دارو یا سایر هوشبرهای هالوژنه؛ القای بیهوشی در کودکان؛ سابقه اختلال کبد پس از بیهوشی.","Known or suspected genetic susceptibility to malignant hyperthermia; sensitivity to this or other halogenated anaesthetics; induction in children; history of hepatic dysfunction after anaesthesia.",[64],{"source":31,"section":55},[66],{"text":67,"refs":70},{"fa":68,"en":69},"هیپرترمی بدخیم؛ هیپرکالمی حین عمل (به‌ویژه میوپاتی‌ها)؛ طولانی شدن QT؛ آسیب کبد؛ نوروتوکسیسیتی احتمالی در کودک زیر ۳ سال با بیهوشی طولانی.","Malignant hyperthermia; perioperative hyperkalaemia (especially myopathies); QT prolongation; hepatic injury; possible neurotoxicity in children under 3 with prolonged anaesthesia.",[71],{"source":31,"section":72},"5",[],[],[],{"status":77,"reviewer":78,"date":78},"unverified",null,[],[81],"N01AB07",{"status":83,"refs":84},"not-found",[85],{"source":86,"section":87,"url":88},"darooyab-generic","G-2665\u002FDesflurane","https:\u002F\u002Fwww.darooyab.ir\u002FG-2665\u002FDesflurane",[90,94,98,101],{"kind":91,"url":92,"label":93},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=020118","NDA020118",{"kind":95,"url":96,"label":97},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=3fe3d468-d283-4dd0-a1a7-29291a9b2d0b","FDA Suprane",{"kind":99,"url":100,"label":81},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N01AB07",{"kind":102,"url":88,"label":8},"darooyab",{"pregnancy":104,"lactation":113,"pediatric":121,"geriatric":129},{"level":105,"text":106,"quote":109,"refs":110},"caution",{"fa":107,"en":108},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate and well-controlled studies in pregnant women.",[111],{"source":31,"section":112},"8.1",{"level":105,"text":114,"quote":117,"refs":118},{"fa":115,"en":116},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Because many drugs are excreted in human milk, caution should be exercised when SUPRANE is administered to a nursing woman.",[119],{"source":31,"section":120},"8.2",{"level":105,"text":122,"quote":125,"refs":126},{"fa":123,"en":124},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Respiratory Adverse Reactions in Pediatric Patients SUPRANE is indicated for maintenance of anesthesia in infants and children after induction of anesthesia with agents other than SUPRANE, and tracheal intubation.",[127],{"source":31,"section":128},"8.4",{"level":105,"text":130,"quote":133,"refs":134},{"fa":131,"en":132},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","The minimum alveolar concentration (MAC) of SUPRANE decreases with increasing patient age.",[135],{"source":31,"section":136},"8.5",{"kind":138,"refs":139,"id":93},"NDA",[140],{"source":31,"section":141},"SPL approval \u002F marketing category",1792444392437]